Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
AB Sciex
FOCUS DIAGNOSTICS, INC.

Affymetrix Will Acquire eBioscience for USD 330 Million

By Labmedica International staff writers
Posted on 26 Dec 2011
Affymetrix (Santa Clara, CA, USA) will acquire eBioscience (San Diego, CA, USA) for USD 330 million in cash subject to customary adjustments. The acquisition is expected to pass the regulatory review period be completed by the end the year 2011. Until then, eBioscience will continue to operate independently.

The acquisition of eBioscience is expected to provide Affymetrix with new commercial opportunities in the key postgenomic applications of immunology, oncology, cell biology, stem cell biology, and diagnostics; diversify the company's revenues to complement its genomics franchise; augment the company's growing business in molecular diagnostics; and expand the company's product portfolio to include multicolor flow cytometry reagents and a broad spectrum of reagents for the analysis of cytokines, growth factors, and other soluble proteins. It should also enhance the operational and new product opportunities for Panomics RNA and protein analysis products and help the commercial capabilities of both companies to generate new opportunities for growth.

Dr. Frank Witney, president and CEO of Affymetrix commented, "With eBioscience, Affymetrix will significantly expand its addressable markets by adding an industry-leading portfolio of cell-based and immunoassays. These new products are a critical part of our customers' workflow in our key target markets of translational medicine, oncology, and immunology.

"We believe that these markets represent a nearly three-billion dollar annual opportunity, which will put Affymetrix on a solid path to sustained growth and profitability. We look forward to welcoming the eBioscience team to the Affymetrix family."

Related Links:
Affymetrix
eBioscience



PURITAN MEDICAL
GREINER-BIO-ONE
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Genetic Tests

view channel

Testing for Atypical Hemolytic Uremic Syndrome Goes NexGen

A patent pending genomic technique that rapidly sequences 12 genes associated with complement-mediated atypical hemolytic uremic syndrome (aHUS) is now being used to diagnose this rare disorder. Atypical hemolytic uremic syndrome (aHUS) is a very rare, life-threatening, progressive disease that frequently has a genetic component.... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more
 

Events

26 Apr 2014 - 30 Apr 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.